• / Free eNewsletters & Magazine
  • / My Account
Home>Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™ (Daclizumab) for Treatment of Multiple Sclerosis

Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™ (Daclizumab) for Treatment of Multiple Sclerosis

3party Content

Fri, 29 Apr 2016

Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™ (Daclizumab) for Treatment of Multiple Sclerosis
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.